Boston keratoprosthesis for the treatment of corneal blindness

Boston Keratoprosthesis for the Treatment of Corneal Blindness: Clinical Effectiveness and Cost-Effectiveness DATE: 22 April 2016 CONTEXT AND POLICY ISSUES Corneal disease is the third most common cause of recoverable blindness in Canada, and the 1-3 most common cause of visual handicap in Canadians under 30 years of age. [...] Summary of Findings Main findings of included studies are summarized in detail in Appendix 5. 1. What is the clinical effectiveness of the Boston type 1 Keratoprosthesis for the treatment of corneal blindness? [...] There was no evidence found on the cost-effectiveness of the KPro for the treatment of corneal blindness. [...] One Canadian study was included in the review, so the generalizability of the findings of the remaining studies to the Canadian setting should be interpreted with caution. [...] Evidence on the clinical effectiveness and safety of KPro must be interpreted with caution since the quality of the included studies is limited by the nature of their non-randomized study designs with potential biases and confounding factors affecting the internal validity of the results such as selection and recall biases.